For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
RediFect™ Red-FLuc-Puromycin Lentiviral Particles are self-inactivating, recombination incompetent lentiviral particles carrying red-shifted Luciola Italica luciferase transgene under control of the stable UbC promoter. The luciferase transgene is fused to the puromycin resistance gene via T2A “self-cleaving” linker peptide for efficient co-expression with selection marker. The lentiviral particles are pseudotyped with G glycoprotein from Vesicular Stomatitis Virus (VSVG), allowing efficient transduction of a wide variety of mammalian cells including most cancer cell lines, primary, stem and non-dividing cells.
We recommend using this product to transduce human cell lines, or murine cell lines that will be used in Nude and SCID mouse models only. An immune response may occur in syngeneic mouse models.
|Optical Imaging Classification||Bioluminescence Imaging|
|Product Brand Name||RediFect|
|Shipping Condition||Dry Ice|
|Unit Size||1 Vial|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.